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TNF-inhibitorsSummary Background: Hepatitis A vaccine is the most frequently used travel vaccine, yet
data are scarce about its ability to induce protection in patients with concurrent immunosup-
pressive treatment. We assessed the immunogenicity of this vaccine in rheumatoid arthritis
(RA) patients treated with tumour necrosis factor-inhibitors (TNFi) and/or methotrexate
(MTX).
Methods: Hepatitis A vaccine was administered to non-immune RA patients at 0 and 6 months.
Hepatitis A virus (HAV) antibodies were assessed at 0, 1, 6, 7, 12, and 24 months with a quan-
titative Chemiluminescent Microparticle Immuno Assay (CMIA) for HAV-IgG. Samples from
month 1, 6, and 7 were, in addition, analysed with a microparticle EIA (MEIA) for anti-HAV
IgM þ IgG.
Results: The final study population consisted of 53 patients treated with TNFi (n Z 15),
TNFi þ MTX (n Z 21) or MTX (n Z 17). One and six months after the first dose, 10% and 33%
of the patients had attained seroprotection. One and six months after the second dose 83%
and 72% were seroprotected. At month 24, 86% of the vaccinees showed protective levels.
Conclusions: Two doses of hepatitis A vaccine at a 6-month interval provided protection for
most immunosuppressed RA patients. A single dose does not seem to afford sufficient protec-
tion to this group of patients.
ª 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
The outstanding anti-inflammatory effect of biological
drugs has made them widely used in the treatment of many
chronic inflammatory conditions. Tumour necrosis factor
inhibitors (TNFi) are the most commonly prescribed bio-
logical drugs. Those suffering from rheumatic conditions
constitute by far the largest group of patients given TNFi,
often accompanied by methotrexate (MTX). Successful
treatment improves the patients’ physical condition,
allowing them to travel more than was possible before.
However, data about immunogenicity induced by travel
vaccines in these patients are scarce.
Tumour Necrosis Factor alpha is a proinflammatory
cytokine. The potent anti-inflammatory effect of TNFi
drugs has proved beneficial in the treatment of various in-
flammatory conditions, such as rheumatoid arthritis (RA).
MTX is a cytotoxic drug used for similar purposes due to its
inhibitory capacity against T-cell activation and its ability
to suppress adhesion molecule expression [1].
Data on vaccine-induced immunogenicity in adult pa-
tients treated with TNFi and/or MTX is mainly limited to
influenza- and pneumococcal vaccinations [2e18]. These
studies have shown that TNFi influences antibody responses
only to a moderate degree, whereas a stronger negative ef-
fect is attributed to concomitant use of MTX [8,10,11,16,18].
Hepatitis A is a highly contagious viral disease that is
widely spread across the globe and, accordingly, hepatitis
A vaccine is one of the most frequently used travel vaccines.
The standard vaccination regimen of two doses administered
from 6 to 12 months apart is known to provide long-standing
immunity for at least 30 years [19]. Hepatitis A vaccines have
been shown to induce protective levels of anti-hepatitis
A virus (HAV) antibodies already 2e4 weeks after the first
dose in 95e100% of adult healthy volunteers [20,21]. The
well-established and reliable anti-HAV antibody response is
widely exploited when vaccinating travellers: to take care of
protection for trips with short notice, one injection is given
before the journey [22,23] and the second only afterwards.Gamma globulin with its efficacy of 80e90% one month
after the injection [24,25] can be used as an alternative to
hepatitis A vaccine for prophylaxis. Yet as gamma globulin
only provides a short-lived protection of 4e8 weeks, it has
generally been replaced by hepatitis A vaccines. Because of
its limited use, gamma globulin may in fact no longer be
available with short notice at travel clinics.
Immunosuppression and advanced age are risk factors
for severe disease and increasing case fatality of hepatitis
A [26]. Moreover, individuals aged 50 years or older have
been shown to develop an impaired response to hepatitis
A vaccine [27]. Apart from one recently published retro-
spective study [28], we are not aware of any other data
about hepatitis A vaccination in adults with chronic in-
flammatory diseases and immunosuppressive treatment.
Since there are no uniform accepted recommendations on
how to protect this group, vaccination practices tend to
vary. We therefore set out to prospectively evaluate im-
mune responses to hepatitis A vaccine in patients with
rheumatoid arthritis treated with TNFi and/or MTX.Material and methods
Study population and design
This outpatient-based, uncontrolled and open-label multi-
centre study was carried out in a real-life setting. We
enrolled adult patients (18 years) with rheumatoid
arthritis (RA, ICD-10 code M59.0 or M06.0) having received
regular treatment with TNFi (etanercept, infliximab, ada-
limumab) and/or methorexate (MTX) for at least one year
and who had plans to travel to a hepatitis A endemic area in
the near future. The exclusion criteria included the
following: a history of hepatitis A disease or vaccination,
allergy to eggs, treatment with rituximab within 9 months
of enrolment or immunosuppressive treatment for diseases
other than RA. The disease activity was estimated with the
28-joints Disease Activity Score (DAS-28, range 0e9) and C -
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was validated with the Health Assessment Questionnaire
(HAQ, range 0e3). Immunoglobulin G (IgG) in serum was
checked at baseline. The inactivated hepatitis A vaccine
regimen routinely used at the given study centre, either
with Havrix or Epaxal, was given intramuscularly in the
deltoid region with a two-dose (0, 6 month) schedule. In-
dividuals with undetectable levels of anti-HAV at month 12
were offered a third dose. Written informed consent was
obtained from all study participants. The study was con-
ducted in accordance with the International Conference on
Harmonisation-Good Clinical Practice (ICH-GCP) guidelines
as well as local regulatory requirements. The study protocol
was approved by the regional ethics committee in Stock-
holm, and registered with the Swedish Medicines Agency
(EUDRACT EU 2009-016055-22) and in the Clinical trials
register (Clin.gov.trials NCT01360970).
Aim of the study
The aim of this study was to explore the proportions of
patients who had an antibody level of anti-HAV  20 mU/
mL at months 1 and 7, after monovalent hepatitis A vaccine
administered by the recommended two-dose schedule (at
months 0 and 6).
Vaccine
One of the two adult hepatitis A vaccines, Havrix given as
a 1.0 ml dose or Epaxal as a 0.5 ml dose, was used ac-
cording to local preferences at the study centres. Havrix
contains 1440 enzyme-linked immunosorbent assay units
(EU) of formalin-inactivated hepatitis A virus. Epaxal
contains at least 24 IE inactivated hepatitis A-viruses,
produced in human diploid (MRC-5) cells, in which the virus
particles are adsorbed to virosomes.
Sample analysis
Blood-samples were drawn at month 0, 1, 6, 7, i.e. before
each vaccination and one month after, as well as 12 and 24
months after the first vaccination dose and, if applicable,
one month after a third dose. Hepatitis A virus (HAV) anti-
bodies were analysed for anti-HAV IgG, using the HAVAb-IgG
Architect System (Abbott) Chemiluminescent Immuno Assay
(CMIA) at the Karolinska University Laboratory, Stockholm,
Sweden. For quantification a standard curve was used by
simultaneously analysing a set of standards (AxSYM HAVAB
2.0 Quantative Standard Calibrators, Abbott) with known
concentrations of HAV antibodies. Initially we intended to
exploit the newer HAVAb-IgG Architect System standardly
used at the Karolinska Institutet. However, as the anti-HAV
responses proved lower than expected, we also applied the
older AxSYM test still employed by a few institutions in
Europe. This assay measures total anti-HAV antibodies; i.e
includes the early IgM response. Thus, samples from month
1, 6 and 7 were also analysed by HAV AB 2.0 quantitative
Assay/AxSYM (Abbott) Microparticle EIA (MEIA) at the
Institute of Virology, Technical University, Munich, Ger-
many. The CMIA-method by the Architect system measures
only anti HAV-IgG and thus misses the very early, mainlyIgM-driven immune response, while the AxSYM method
(MEIA) detects both anti-HAV IgM and IgG combined [29].
Definition of seroprotection
The protective level of antibodies against hepatitis A was
defined as anti-HAV  20 mIU/mL. The lower limit of
detection (LLD) was 10 mIU/mL. Geometric mean concen-
trations (GMC) were calculated, with corresponding 95%
confident intervals (CI), using half of the LLD (5 mIU/mL)
for negative sera. An “adjusted” GMC were calculated from
the subgroup with anti-HAV  10 mIU/mL only, i.e. the
negative sera were withdrawn so as to demonstrate better
the anti-HAV antibody levels of those responding to the
vaccine.
Anti-HAV  10 mIU/mL has been accepted as a measure
of protection in recent years [24], therefore data were also
presented in relation to this limit.
Safety
All participants were asked to report any kind of adverse
event possibly related to the HAV-vaccination at every visit
scheduled for vaccination or blood sampling. They were
also carefully instructed to report any adverse events or
contact with health care between these visits.
Statistics
GMCs with 95% CI were calculated using SAS Enterprise Guide
version 5.1 version. Basic statistical analysis was performed
with Excel. Differences were analysed with a two-sided test.
The level of statistical significance was set at p < 0.05.
Results
Demographics
During the study period we included 68 patients (Fig. 1).
Fifteen patients were found to be anti-HAV positive in pre-
vaccination samples suggesting either a previous history of
hepatitis A disease or a vaccination which they no longer
remembered. These patients had been given one dose of
vaccine at the time of inclusion but were then excluded
from further analyses. The final study population consisted
of 53 non-immune patients (73% women) with a median age
of 60 years (mean 56; range 32e75). The median disease
activity scores indicated a low disease activity and the daily
function score a relatively physically active cohort of pa-
tients. Fifteen patients (28%) were treated with TNFi only
(etanercept, infliximab or adalimumab), 21 (40%) with a
combination of TNFi and MTX and 17 (32%) with MTX only
(Fig. 1). None of the patients had been treated with rit-
uximab ever before. Baseline characteristics, divided by
treatment groups, are shown in Table 1.
Vaccines
Epaxal was given to 32 patients at two different study
centres, and Havrix to 21 patients at one study centre.
Fig. 1 Study schedule. TNFi Z TNF-inhibitors. MTX Z methotrexate.
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Fifty-two patients were included in per protocol analysis
and their samples were available for months 1, 7 and 12
(Fig. 1). Fifty-one samples were available for analysis of the
post-vaccination titres at 6 months. Ten percent (5/52)
reached the pre-defined immunity level of anti-
HAV  20 mIU/mL one month after the first dose of vaccine.
Thirty-three percent (17/51) reached protective levels
after six months, before the second dose. At months 7 and
12, i.e. one and 6 months after the second vaccine dose,
83% (42/52) and 72% (37/52) of the patients were anti-HAV
positive, respectively. The corresponding results when
accepting the lower immunity level of 10 mIU/mL at
month 1, 6, 7 and 12 were 29% (15/52), 45% (23/51), 84%
(43/52) and 77% (40/52). Twenty-nine out of 37 patients
with an anti-HAV  20 mIU/mL at month 12 provided a
follow-up sample at month 24; the antibody level was20 mIU/mL in 25/29 (86%) of these, between 10 and
20 mIU/mL in 2/29 (7%) and under the lower detection limit
in 2/29 (7%, both patients had TNFi þ MTX). Eight patients
with anti-HAV levels below the detection limit at month 12
were given a third vaccine dose and 4/8 responded with an
antibody titre above 20 mIU/mL (range 32e110) at one
month post vaccination. With respect to the three different
treatment groups, the proportion of patients with anti-HAV
20 mIU/mL at month 1 was higher in the TNFi (20%) than
in the TNFi þ MTX (5%) and MTX (6%) groups, yet the dif-
ference between groups did not prove statistically signifi-
cant (Fig. 2a). Using the lower level of protection (anti-HAV
10 mIU/L), there was a significant difference between the
TNFi group (73%) and others (15%, 6%) at month 1, indi-
cating a potential for reaching protection after one vaccine
dose only, in patients treated with TNFi only (Fig. 2b). The
GMC values obtained with the two methods and corre-
sponding 95% confidence intervals are displayed in Table 2.
Table 1 Baseline characteristics of the 53 patients anti-HAV negative at inclusion as evaluated before vaccination, in the
different treatment groups. TNFi Z TNF-inhibitor. MTX Z Methotrexate. All variables are medians unless other information
given.
All (range) TNFi TNFi þ MTX MTX
N 53 15(28%) 21(40%) 17(32%)
Age (yrs) 60 (32e75) 49 61 61
Female (%) 73% 80% 71% 70%
Duration of the disease (yrs) 12 (2e45) 12 14 6
Time span since last TNFi-infusion (days) 6 (0e49) 3 7 NA
MTX weekly dose (mg) 15 (7.5e22.5) NA 15 15
DAS-28a 2.66 (0.49e5.89) 3.17 2.48 2.38
HAQb 0.75 (0e1.88) 0.75 0.75 0.5
C- reactive protein mg/l 2 (0e46) 3 3 0
Immunoglobulin G g/l 11.2 (5.9e18.8) 12.6 11.3 9.7
Prednisonec (no of patients) 15 4 4 7
NSAIDd (no of patients) 5 4 3 0
Salazopyrin (no of patients) 2 1 1 0
Anti-malarial drugs (no of patients) 3 0 0 3
a 28-joints Disease Activity Score (DAS-28, 0e9).
b Health Assessment Questionnaire (HAQ, 0e3).
c Prednisone dose (median 5 mg, range 1.25e10 mg).
d NSAID Z Non Steroidal Anti Inflammatory Drugs.
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dose was consistent with the higher sensitivity reported
with the AxSYM-method analysing also the early IgM-
response: 10% of the patients reached a protective level
of anti-HAV  20 IU/mL and 29% a level of 10 mIU/mL
compared to 1% for both levels with the CMIA-method.
There was no difference between the two methods, with
respect to proportion of seroprotected patients, beyond
month 1.Non-responders at month 7
Ten out of 52 patients (19%) lacked a serological response
(one of these had a level between 10 and 20 mIU/mL) after
two doses of hepatitis A-vaccine at month 7. In this group
the median age was 62 years, 5/10 were women and 1/10
were treated with TNFi, 4/10 with TNFi þ MTX and 5/10
with MTX.Safety
One patient died of a heart-attack 10 days after the first
vaccine dose (Epaxal). The study team in cooperation with
the cardiologist considered the death to be due to known
co-morbidities and an association with the vaccine was
deemed unlikely. One female patient was hospitalized due
to meningo-encephalitis 2.5 weeks after the second dose
(Epaxal). This patient recovered but TNF-inhibitor treat-
ment was interrupted as the aetiology remained unknown.
Two patients reported mild reversible adverse event of
slight vertigo (Havrix) and non-itching exanthema
(Epaxal), both of them 1e2 days after the second vaccine
dose. There was no evidence suggesting increased disease
activity of RA in the follow-up of any of the study patients.Premature termination of the study due to lack of
protective pre-travel immunity
Initial we planned to include 330 patients, as suggested by
pre-study power calculation based on reports of one vac-
cine dose being non-inferior to gamma globulin in terms of
seroprotection. However, we considered it unethical either
to include immunosuppressed patients not needing the
vaccine, or to carry on once the first interim results had
revealed that the short-term immunity could not be guar-
anteed for patients receiving only one dose. These results
were not only unexpected but also a strong signal that
rendered the power calculation invalid. Patients having not
reached protective levels of anti-HAV (20 mIU/mL) in
their last samples were informed that they should be given
gamma globulin as a pre-travel prophylaxis.
Discussion
The present study is the first to prospectively investigate
the immune response to hepatitis A vaccine in adult pa-
tients treated with TNF-inhibitors and/or methotrexate.
The results reveal an insufficient antibody response one
month after the first dose of inactivated hepatitis A
vaccine.
Current practices of using HAV vaccines and
reasons for terminating the study
Several studies have shown that in healthy individuals one
dose of hepatitis A vaccine renders seroprotection
[20,21,30]. Accordingly, it is a common practice to take
care of short-term protection for a pending trip by giving
only one dose to naive travellers. This would also appear to
Fig. 2 Proportion of RA patients (%) with (a) anti-HAV  20 mIU/mL and (b) anti-HAV  10 mIU/mL divided by treatment group
(TNFiZ TNF-inhibitors, MTXZ methotrexate). NZ 52. Hepatitis A vaccine was given as single doses at months 0 and 6. For month
1 anti-HAV IgG þ IgM data (analysed with HAV AB 2.0 quantitative Assay/AxSYM Mikropartikel EIA, MEIA) and for months 6, 7 and 12
anti-HAV IgG data (analysed with HAV Ab Architect System Chemiluminescent Microparticle Immuno Assay, CMIA) are presented.
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taking immunosuppressive drugs, since other types of vac-
cines have been shown to induce protective levels of anti-
bodies in this group [2,8e14,16]. Advanced age is a factor
related to an impaired antibody response [27], and the
median age of our population of RA patients was 60 years.
However, the age-group was similar to studies with pneu-
mococcal and influenza vaccinations showing adequate
immune-response [2,8e14,16]. Therefore inadequate anti-
body responses observed in the present study one month
after vaccinations were unforeseen. As the patients were
planning to travel soon, it was considered unethical to
continue the study when the protocol could not grant them
protection against hepatitis A. Premature termination of
the study resulted in inclusion of fewer subjects than
intended.
Comparison with other studies
We know of only one recently published paper dealing with
seroprotection after Hepatitis A vaccination in patients
with drug-induced immunosuppression [28]. It was
concluded in that retrospective study that one dose of
vaccine does not provide seroprotection. This is consistent
with our findings, yet the data of that study should be
compared with caution, since the underlying inflammatory
diseases and seroprotective level were not defined, and the
pre-vaccination anti-HAV status of the patients was un-
known. This illustrates the difficulties of a retrospective
design and motivates our prospective outline of a homog-
enous patient group.
Studies of other vaccines
Studies of inactivated trivalent influenza vaccines have
shown that although TNFi treatment moderately decreases
humoural responses, the patients still develop protective
antibody levels [2,3,12e14], and the response can even
equal that in healthy controls [11]. The aforementioned
studies were conducted in RA patients, yet one study also
included patients with other chronic illnesses [3]. Pneu-
mococcal polysaccharide and conjugate vaccines have been
reported to elicit an equal [8,10,11,16], or only slightlyimpaired [9] antibody response in TNFi-treated RA patients
compared to healthy controls. A moderate decrease in
antibody levels has been found in inflammatory bowel dis-
ease (IBD) patients on TNFi [6]. Notably, several studies of
pneumococcal and influenza vaccines have demonstrated
the immunosuppressive effect to be reinforced by
concomitant use of MTX [2,8,11,15,16,18]. These findings
are consistent with our data showing that 9/10 non-
responders, after two hepatitis A vaccine doses, belonged
to groups treated with MTX alone or in combination with
TNFi. The proportion of patients who attained protective
levels at month one appeared significantly higher in the
group treated solely with TNFi compared to the other two
groups, yet a statistical significance could only be verified
when using anti-HAV antibodies 10 mIU/mL as a limit of
protection (Fig. 2a and b).
Our data, like most of the studies quoted above, strictly
applies only to patients with RA which is the largest group
of patients treated with biological drugs such as TNFi.
Other inflammatory conditions elicit diverse inflammatory
responses and patients may be prescribed other drug
combinations, which might interfere with the serological
response in a different way. Further studies are needed to
investigate those other patients groups.
Methodological considerations
In studies of healthy individuals, estimates of the minimum
levels of serum anti-HAV antibodies required for protection
have varied between 10 and 33 mIU/mL, yet the lowest
level providing protection against HAV remains undeter-
mined [31]. Due to these differences, we present our re-
sults with the cut-off 20 mIU/mL used in the CMIA
method, and in addition also with 10 mIU/mL to allow
comparison with studies using this cut-off. Difference in the
results obtained by the two methods at month one did not
influence our decision to terminate the study, since the
proportion of patients protected with one dose remained
too low altogether. The use of two methods strengthens our
findings, demonstrating also the advantages of anti-HAV IgM
measurements in this population. It is noteworthy that even
though cell-mediated immunity in healthy individuals may
contribute significantly to protection against disease, in
immunosuppressed older patients the risk of getting
Table 2 Geometric Mean Concentrations (GMC) anti-HAV antibody responses in 52 RA patients receiving hepatitis A vaccine at
0 and 6 months. The protective level of anti-HAV antibodies was defined as 20 mIU/mL. The lower limit of detection (LLD) was
10 mIU/mL. The results are shown with the two different serological assays; HAV Ab Architect System Chemiluminescent
Microparticle Immuno Assay (CMIA) and HAV AB 2.0 quantitative Assay/AxSYM Mikropartikel EIA (MEIA) (the latter not tested at
12 and 24 months). The results are given as a) Geometric Mean Concentrations (GMC) of anti-HAV antibodies (mIU/mL) with 95%
confidence intervals (CI) at 1,6,7,12 and 24 months. GMC was calculated using half of the LLD (5 mIU/mL) for negative sera. b)
“Adjusted” Geometric Mean Concentrations (GMC), including only the subpopulation with antibody levels anti-HAV  10 mIU/
mL, i.e withdrawing all the negative sera to better demonstrate the anti-HAV antibody levels of those who responded to the
vaccine. This is shown with 95% confidence intervals (CI) at 1,6,7,12 and 24 months.
Method Month 1 Month 6 Month 7 Month 12 Month 24
a
HAV Ab Architect System
Chemiluminescent
Microparticle
Immuno Assay (CMIA)
5.2 (4.8e5.6) 11.8 (8.7e16) 45.4 (32.8e62.8) 35.7 (25.3e50.3) 43.1 (30.6e60.8)
HAV AB 2.0 Assay/AxSYM
(Abbott)
Mikropartikel EIA (MEIA)
7.5 (6.3e8.9) 12.6 (8.8e17.9) 109.3 (60.8e196.5) NA NA
b
HAV Ab Architect System
Chemiluminescent
Microparticle
Immuno Assay (CMIA)
NAa 36.6 (27.3e48.9) 71.9 (59.5e87.1) 64.3 (51.8e79.8) 49.6 (37.4e65.6)
HAV AB 2.0 Assay/AxSYM
(Abbott)
Mikropartikel EIA (MEIA)
16.3 (13.5e19.8) 42.3 (26.5e67.6) 182.7 (106.6e313.3) NA NA
a Only one observation with anti-HAV  10 mIU/mL.
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should not be relied on, if the antibody level is below
10e20 mIU/mL.
Recommendations for practical use
As one dose does not seem to suffice to provide short-term
protection in these patients, the only reasonable choice at
the moment is to use gamma globulin. Another option
would be to give the vaccine and gamma globulin at the
same time or, as suggested before [32] but not yet studied,
two vaccine doses at one-month intervals. A different so-
lution can be applied to patients not travelling in the six-
month period post initial vaccination, since a sufficient
serological response was seen in 83% of the patients one
month after the second dose. Importantly, in the group on
TNFi only, 73% had attained seroprotection by anti-HAV
10 mIU/mL after one vaccine dose, while in the
TNFi þ MTX and MTX group, only 15% and 6% were protected
after one month. This implies that for patients treated
solely with TNFi and travelling with short notice, one dose
of hepatitis A vaccine might be considered, although this
needs to be confirmed in a larger study. Our data indicate
that patients with inflammatory conditions should prefer-
ably be given the first dose of hepatitis A vaccine upon
diagnosis, or at least prior to immunosuppressive treat-
ment. This approach has in fact also been recommended for
other inactivated vaccines e.g. pneumococcal and hepatitis
B as well as for live vaccines, if a future need for these
vaccines is anticipated [33,34].Limitations of the study
The main limitation of this study is the lack of a relevant
control group. However, we considered the robust and
repeated data on serological hepatitis A vaccine response in
healthy individuals so well established [35] that any devi-
ation from that will be an important signal and lead to quick
reporting. The latter appears imperative, also, from the
perspective that the reports on adequate overall serolog-
ical response in RA-patients of the same age-group after
influenza- and pneumococcal vaccination made us expect
the same for hepatitis A vaccine. Another limitation of the
study is the small sample size, a consequence of the pre-
mature termination due to ethical concern of travellers
unprotected to hepatitis A. The small sample size limits the
external validity of the study. It also renders any conclu-
sions on subgroups, such as age, gender, TNFi group, diffi-
cult to interpret.Strength of the study
The findings indicate an important signal that should be
studied further in a prospective study with a larger number
of volunteers, and in patients with other immunosuppres-
sive conditions. In lack of data, health care professionals
might unintentionally send their patients off unprotected
to hepatitis A risk areas. Our results are also consistent with
studies in the same patient group on influenza and
pneumococcal vaccination concerning the fact that
Hepatitis A vaccine for immunosuppressed patients with rheumatoid arthritis 141monotherapy with TNFi is not influencing serological vac-
cine response significantly. Moreover our results proved
consistent by two different serological methods. These
data also attested to the importance of measurement of
anti-HAV IgM in early post-vaccination response.
Conclusions
Two doses of hepatitis A vaccine given six months apart can
be considered to provide protective immunity to most
travellers having RA treated with TNFi and/or MTX. In
contrast to recommendations for healthy travellers, a sin-
gle of hepatitis A vaccine dose does not suffice as pre-
exposure prophylaxis for these patients, except may be
patients treated with TNFi only. Larger studies are required
to confirm this, and to determine if increased dosage or a
second priming dose of the vaccine could provide adequate
protection. Until then, for journeys with a time span of six
months or shorter, travellers should be protected with
gamma globulin.
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